-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $36

Benzinga·10/13/2026 15:59:38
Listen to the news
TD Cowen analyst Dan Brennan maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $30 to $36.